Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Maruho Gets Asia Rights to Hyperhidrosis Wipe Drug
September 8, 2023
- Keytuda Filed in Japan in NSCLC Neoadjuvant/Adjuvant Setting: MSD
September 8, 2023
- Brexpiprazole Combo Logs Mixed Results in 2 PTSD Trials: Otsuka/Lundbeck
September 8, 2023
- Noile-Immune Hits Early Milestone for CAR-T Tech Transfer to Chugai
September 7, 2023
- PNH Drug Crovalimab Accepted for FDA Review: Chugai
September 7, 2023
- Daiichi Sankyo’s Omicron-Tailored Booster Hits Main Goal: Japan PIII
September 7, 2023
- Keytruda Nabs Top Slot in Japan Sales Ranking, 1st Time in 2 Years: Encise
September 7, 2023
- BMS Gets Rights to Zenas Antibody in Japan, Korea, and More Regions
September 7, 2023
- Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
- Sawai Poised to Respond to Generic System Reform and Raise Productivity: New President
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
- Nucala Filed in Japan for Chronic Rhinosinusitis with Nasal Polyps: GSK
September 5, 2023
- Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
- Otsuka to Acquire Canada’s Psychedelic Specialist Mindset Pharma
September 4, 2023
- Enhertu Gets 2 More Breakthrough Therapy Tags in US: Daiichi Sankyo
September 4, 2023
- Shionogi Wins SCARDA R&D Funding for Nasal Vaccines for Flu, COVID
September 1, 2023
- Atozet Generic to Hit Japan Shelves on Sept. 1
September 1, 2023
- Ono, Twist Bio Tie Up on Antibody Discovery for Autoimmune Disorders
September 1, 2023
- 2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
September 1, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…